drugset / Trial / NCT07447102
Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a multicenter, Phase II clinical study to evaluate the efficacy and safety of BC006 over a 24-week treatment period in patients with idiopathic pulmonary fibrosis (IPF). The study consists of two phases: an open-label safety run-in phase and a double-blind, randomized, placebo-controlled phase.
Timeline
- Start
- 2026-04-27
- Primary completion
- 2029-04-01
- Completion
- 2029-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BC006 | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | BC006 | Monoclonal antibody | 1 mg/kg | Intravenous |